Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies

This study was designed to evaluate dosimetric, pharmacokinetic, and other treatment-related parameters as predictors of outcome in patients with advanced B-lymphocytic malignancies. Fifty-seven patients were treated with radiolabeled Lym-1 antibody in early phase trials between 1985 and 1994. Logis...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 1997-08, Vol.3 (8), p.1253-1260
Main Authors: LAMBORN, K. R, DENARDO, G. L, DENARDO, S. J, GOLDSTEIN, D. S, SHEN, S, LARKIN, E. C, KROGER, L. A
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Heterophile - blood
Antibodies, Monoclonal
Antineoplastic agents
Biological and medical sciences
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Copper Radioisotopes - pharmacokinetics
Copper Radioisotopes - therapeutic use
Female
Heterocyclic Compounds - pharmacokinetics
Heterocyclic Compounds - therapeutic use
Humans
Iodine Radioisotopes - pharmacokinetics
Iodine Radioisotopes - therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Leukemia, Lymphocytic, Chronic, B-Cell - radiotherapy
Lymphoma, B-Cell - mortality
Lymphoma, B-Cell - pathology
Lymphoma, B-Cell - radiotherapy
Male
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Staging
Organometallic Compounds - pharmacokinetics
Organometallic Compounds - therapeutic use
Pharmacology. Drug treatments
Proportional Hazards Models
Radioimmunotherapy
Radiopharmaceuticals - pharmacokinetics
Radiopharmaceuticals - therapeutic use
Regression Analysis
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was designed to evaluate dosimetric, pharmacokinetic, and other treatment-related parameters as predictors of outcome in patients with advanced B-lymphocytic malignancies. Fifty-seven patients were treated with radiolabeled Lym-1 antibody in early phase trials between 1985 and 1994. Logistic regression and proportional hazards models were used to evaluate treatment parameters for their ability to predict outcome, taking into account patient risk group based on Karnofsky performance status and serum lactic dehydrogenase. The occurrence of a partial or complete response (31 of 57 patients) and development of human antimouse antibody (HAMA) predicted improved survival using a time-dependent proportional hazards model. The final multivariate model for survival with parameters significant at P
ISSN:1078-0432
1557-3265